SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                       ----------------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                                October 27, 1998
                Date of Report (Date of earliest event reported)

                             AVAX TECHNOLOGIES, INC.
             (Exact name of Registrant as specified in its charter)

          Delaware                     000-29222               13-3575874
(State or other jurisdiction   (Commission File Number)       (IRS Employer
     of incorporation)                                   Identification Number)

                                4520 Main Street
                                    Suite 930
                              Kansas City, MO 64111
                    (Address of principal executive offices)

                                 (816) 960-1333
              (Registrant's telephone number, including area code)


                                Page 1 of 5 Pages
                         Exhibit Index Appears at Page 3
<PAGE>

Item 5. Other Events

            AVAX Technologies, Inc. (the "Company") announced on Tuesday,
October 27, 1998 that it has initiated its 15th U.S. clinical site for its
pivotal registration trial of M-Vax(TM), an experimental autologous vaccine for
treating Stage 3 melanoma. The Company's randomized, multi-center registration
trial is designed to compare the efficacy of M-Vax against that of high dose
alpha interferon.

            Reference is made to the Company's related press release attached
hereto as Exhibit 99.21 and incorporated by reference herein (including, without
limitation, the information set forth in the cautionary statement contained in
the final paragraph of the press release).

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits

         (c)      Exhibit:

                  99.21 Press Release dated October 27, 1998.

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   AVAX TECHNOLOGIES, INC.

Date: October 28, 1998


                                   By:    /s/ Jeffrey M. Jonas
                                          -------------------------------------
                                   Name:  Jeffrey M. Jonas, M.D.
                                   Title: President and Chief Executive Officer


                                       2
<PAGE>

                                  Exhibit Index

      Exhibit Number                                Description
      --------------                                -----------

          99.21                         Press Release dated October 27, 1998.


                                       3
[{"type": "8-K", "sequence": "1", "description": "FORM 8-K", "secsgml_size_bytes": 3097}]
{"company-data": {"conformed-name": "AVAX TECHNOLOGIES INC", "cik": "0001015441", "assigned-sic": "2836", "irs-number": "133575874", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-29222", "film-number": "98732209"}, "business-address": {"street1": "4520 MAIN ST", "street2": "STE 930", "city": "KANSAS CITY", "state": "MO", "zip": "64111", "phone": "8169601333"}, "mail-address": {"street1": "4520 MAIN STREET SUITE 930", "city": "KANSAS CITY", "state": "MO", "zip": "64112"}}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                       ----------------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                                October 27, 1998
                Date of Report (Date of earliest event reported)

                             AVAX TECHNOLOGIES, INC.
             (Exact name of Registrant as specified in its charter)

          Delaware                     000-29222               13-3575874
(State or other jurisdiction   (Commission File Number)       (IRS Employer
     of incorporation)                                   Identification Number)

                                4520 Main Street
                                    Suite 930
                              Kansas City, MO 64111
                    (Address of principal executive offices)

                                 (816) 960-1333
              (Registrant's telephone number, including area code)

                                Page 1 of 5 Pages
                         Exhibit Index Appears at Page 3
Item 5. Other Events

            AVAX Technologies, Inc. (the "Company") announced on Tuesday,
October 27, 1998 that it has initiated its 15th U.S. clinical site for its
pivotal registration trial of M-Vax(TM), an experimental autologous vaccine for
treating Stage 3 melanoma. The Company's randomized, multi-center registration
trial is designed to compare the efficacy of M-Vax against that of high dose
alpha interferon.

            Reference is made to the Company's related press release attached
hereto as Exhibit 99.21 and incorporated by reference herein (including, without
limitation, the information set forth in the cautionary statement contained in
the final paragraph of the press release).

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits

         (c)      Exhibit:

                  99.21 Press Release dated October 27, 1998.

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   AVAX TECHNOLOGIES, INC.

Date: October 28, 1998

                                   By:    /s/ Jeffrey M. Jonas
                                          -------------------------------------
                                   Name:  Jeffrey M. Jonas, M.D.
                                   Title: President and Chief Executive Officer

                                       2
Exhibit Index

      Exhibit Number                                Description
      --------------                                -----------

          99.21                         Press Release dated October 27, 1998.

                                       3